Allergy Asthma Respir Dis.  2014 Nov;2(5):394-397. 10.4168/aard.2014.2.5.394.

Successful desensitization for cytarabine induced anaphylaxis

• Lee HW
• Park JY
• Moon JH
• Park KT
• Park HK
• Kang HR

• KMID: 1803550
• DOI: http://doi.org/10.4168/aard.2014.2.5.394

Abstract

Cytarabine is a very important chemotherapeutic agent for leukemia and lymphoma patients and is prescribed more frequently than before. Cytarabine-induced delayed-onset hypersensitivity may rarely present as non-IgE mediated anaphylaxis. However, we do not know yet whether desensitization therapy in adults may be effective in cytarabine-induced delayed-onset anaphylaxis. A 78-year-old woman who was diagnosed with acute myeloblastic leukemia had chemotherapy including cytarabine. In spite of premedication with hydrocortisone and chlorpheniramine, the patient had anaphylaxis a few hours after cytarabine infusion. We decided to perform desensitization therapy. After desensitization therapy using a newly designed protocol, the patient was tolerable to cytarabine infusion without hypotension or high fever. Desensitization therapy was successfully performed on an adult patient with delayed-onset anaphylaxis caused by cytarabine.

Keyword

Anaphylaxis; Cytarabine; Immunologic desensitization

MeSH Terms

Adult
Aged
Anaphylaxis*
Chlorpheniramine
Cytarabine*
Desensitization, Immunologic
Drug Therapy
Female
Fever
Humans
Hydrocortisone
Hypersensitivity
Hypotension
Leukemia
Leukemia, Myeloid, Acute
Lymphoma
Premedication
Chlorpheniramine
Cytarabine
Hydrocortisone

Figure

• 

  Fig. 1 Hypotension and peak fever over 39℃ occurred after cytarabine infusion, however, vanished after desensitization. SBP, systolic blood pressure.

Reference

1. Moreno-Ancillo A, Dominguez-Noche C, Gil-Adrados AC, Cosmes PM, Duarte I, Mateos Y. Anaphylactoid reaction to carboplatin: successful "desensitization". Allergol Immunopathol (Madr). 2003; 31:342–344.

2. Essayan DM, Kagey-Sobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol. 1996; 97(1 Pt 1):42–46.

3. Simons FE. World Allergy Organization. World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings. Ann Allergy Asthma Immunol. 2010; 104:405–412.

4. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001; 161:15–21.

5. Ek T, Jarfelt M, Mellander L, Abrahamsson J. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol. 2001; 37:459–464.

6. Markman M, Howell SB, King M, Pfeifle C, Wasserman SI. Anaphylactic reaction to cytarabine: in vitro evidence that the response is immunoglobulin E mediated. Med Pediatr Oncol. 1984; 12:201–203.

7. Rassiga AL, Schwartz HJ, Forman WB, Crum ED. Cytarabine-induced anaphylaxis. Demonstration of antibody and successful desensitization. Arch Intern Med. 1980; 140:425–426.

8. Williams SF, Larson RA. Hypersensitivity reaction to high-dose cytarabine. Br J Haematol. 1989; 73:274–275.

9. Lin RY. Desensitization in the management of vancomycin hypersensitivity. Arch Intern Med. 1990; 150:2197–2198.

10. Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A, et al. Desensitization in delayed drug hypersensitivity reactions: an EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013; 68:844–852.

11. Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev. 2007; (2):CD005646.

12. Whitaker P, Shaw N, Gooi J, Etherington C, Conway S, Peckham D. Rapid desensitization for non-immediate reactions in patients with cystic fibrosis. J Cyst Fibros. 2011; 10:282–285.

13. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005; 96:824–829.